Dovato Treatment Considerations

Patient Evaluation and Monitoring

Renal function assessment is essential before initiating Dovato, as dolutegravir causes a 10% increase in serum creatinine through tubular secretion blockade without affecting true glomerular filtration rate, and patients with creatinine clearance below 30 mL/min should not use Dovato 1
The American Academy of HIV Medicine recommends monitoring renal function every 3-6 months in patients taking Dovato, expecting a small increase in serum creatinine from dolutegravir's effect on tubular secretion without true kidney injury 1
In virologically suppressed patients switching to Dovato, HIV RNA should be checked 1 month after the switch to ensure suppression is maintained, as recommended by the HIV Medicine Association 3

Patients with HBV co-infection require a tenofovir-based regimen plus lamivudine or emtricitabine to provide dual HBV activity, according to the Infectious Diseases Society of America 3
The European AIDS Clinical Society recommends that Dovato is absolutely contraindicated in patients with active HBV co-infection, as the regimen lacks adequate HBV coverage and risks hepatitis flares upon discontinuation 2

Dolutegravir has minimal drug interactions with hepatitis C direct-acting antivirals, making Dovato suitable for HCV co-infected patients, though specific DAA regimen selection requires attention, as noted by the American Association for the Study of Liver Diseases 5, 2
The International AIDS Society recommends that acid-reducing agents do not significantly affect dolutegravir absorption, unlike other integrase inhibitors, and rifampin and other potent enzyme inducers require dolutegravir dose increase to 50 mg twice daily 1

The World Health Organization recommends that patients with documented or suspected integrase inhibitor resistance should not use Dovato, as the two-drug regimen lacks sufficient genetic barrier in this setting 3
Patients with prior virologic failure on integrase inhibitor-based regimens require resistance testing and typically need a boosted protease inhibitor-based regimen, according to the British HIV Association 3